cc-99677
Small moleculeexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 23, 2018 (NCT03554993)
Timeline
Indications
Mechanism of action
MAPKAPK2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05445440 | Phase 1 | Sep 6, 2022 | Bristol-Myers Squibb |
| NCT05284890 | Phase 1 | May 12, 2022 | Bristol-Myers Squibb |
| NCT04947579 | Phase 2 | Aug 25, 2021 | Celgene |
| NCT04958291 | Phase 1 | Jul 14, 2021 | Celgene |
| NCT04718636 | Phase 1 | Sep 30, 2020 | Bristol-Myers Squibb, Celgene |
| NCT04268394 | Phase 1 | Feb 15, 2020 | Celgene |
| NCT03554993 | Phase 1 | May 23, 2018 | Celgene |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 5 | 5 | 2 | 2018 |
| Bristol-Myers Squibb | For profit | 3 | 2 | 1 | 2020 |
2 organizations
Page 1 / 1